HIV Gene Therapy

Cre-loxP Hammerhead Ribozyme Inhibits HIV-1 Replication

Published in Gene Therapy Weekly, November 9th, 2000

Researchers in Japan report that the Cre-loxP hammerhead ribozyme can inhibit HIV-1 replication.

"An alternative strategy has been the use of antiviral genes that are delivered to uninfected cells as either RNA or DNA and provide intercellular protection from HIV-1," stated Y. Habu and colleagues from the Chiba Institute of Technology, Narashino. "Antiviral genes include those encoding antisense molecules, ribozymes, transdominant proteins, and intracellular antibodies."

Habu et al. presented data from their study at the XIV International Roundtable, Nucleosides, Nucleotides, and their Biological Applications, held September 10-14, 2000, in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-11-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry